// App-Quantinova.ai

188 : Impact of Baseline Disease Activity, Disease Duration and Enrolment Year on CDAI and Boolean Remission in Patients with Rheumatoid Arthritis Treated with Anti-TNF-Alpha Therapy: An Analysis from a Prospective, Observational Registry

Researchers

Presenter

  • Michael Starr

Principal Investigators

  • Louis Bessette

  • Karina Maslova

  • Allen Lehman

  • Cathy Tkaczyk

  • Philip Baer

  • Regan Arendse

  • Isabelle Fortin

  • Dalton Sholter

  • Eliofotisti Psaradellis

  • Angeliki Karellis

  • Brendan Osborne

  • Francois Nantel

Medical Centers

  • University of Alberta, Edmonton, AB, Canada

  • CH Rimouski, Rimouski,Canada

  • Institut de Rhumatologie, Montreal, QC, Canada

  • University of Saskatchewan, Saskatoon, SK, Canada

  • McGill, Montreal, QC, Canada

Locations

  • Canada

Companies

  • JSS Medical Research

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

  • Rheumatoid arthritis

  • Psoriatic arthritis

  • Inflammatory Arthritis

Biomarkers

  • C reactive protein

  • Albumin/creatinine

Drug/Treatment

  • Infliximab

  • golimumab

Outcome

  • Unknown

Study Design

  • observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved